DelveInsight’s, “Methicillin-Resistant Staphylococcus Aureus Infections Pipeline Insight 2024” report provides comprehensive insights about 25+ companies and 27+ pipeline drugs in Methicillin-Resistant Staphylococcus Aureus Infections pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Methicillin-Resistant Staphylococcus Aureus Infection Research. Learn more about our innovative pipeline today! @ Methicillin-Resistant Staphylococcus Aureus Infection Pipeline Outlook
Key Takeaways from the Methicillin-Resistant Staphylococcus Aureus Infection Pipeline Report
- In September 2024:- AbbVie- A Phase 3, Multicenter, Open-Label, Randomized, Comparator Controlled Trial of the Safety and Efficacy of Dalbavancin Versus Active Comparator in Pediatric Subjects With Acute Bacterial Skin and Skin Structure Infections. To determine the safety and descriptive efficacy of dalbavancin for the treatment of acute bacterial skin and skin structure infections in children, aged birth to 17 years (inclusive), known or suspected to be caused by susceptible Gram-positive organisms, including methicillin-resistant strains of Staphylococcus aureus.
- DelveInsight’s Methicillin-Resistant Staphylococcus Aureus Infection pipeline report depicts a robust space with 25+ active players working to develop 27+ pipeline therapies for Methicillin-Resistant Staphylococcus Aureus Infection treatment.
- The leading Methicillin-Resistant Staphylococcus Aureus Infection Companies such as Trellis Bioscience, LegoChem Biosciences, Aptorum Group, ContraFect, Crystalgenomics, Cellics Therapeutics, MicuRx, Oxford Antibiotic Group, Destiny Pharma, TSRL, Inc., TAXIS Pharmaceuticals, Basilea Pharmaceutica, Helperby Therapeutics, Akagera Medicines, Histogen, Alphamab Co. Ltd, Biocidium Pharmaceuticals, and others.
- Promising Methicillin-Resistant Staphylococcus Aureus Infection Therapies such as Retapamulin, Linezolid (Zyvox), Vancomycin, Nitric Oxide, Ceftaroline fosamil, Daptomycin, and others.
Stay informed about the cutting-edge advancements in Methicillin-Resistant Staphylococcus Aureus Infection Treatments. Download for updates and be a part of the revolution in care @ Methicillin-Resistant Staphylococcus Aureus Infection Clinical Trials Assessment
Methicillin-Resistant Staphylococcus Aureus Infection Emerging Drugs Profile
- HY-004B8b: Helperby Therapeutics
Helperby has discovered and is developing a suite of Antibiotic Resistance Breakers (ARBs). These compounds, when combined with old antibiotics, can restore the original potency against both Gram positive and Gram negative bacteria. Helperby’s HY-004 project is in phase II trials for effectiveness against nasal MRSA decolonisation.
- TRL1068: Trellis Bioscience
TRL1068 is a high affinity mAb that targets the DNABII protein family; BLAST analysis has found hundreds of DNABII homologs across many bacterial species. TRL1068 is broad-spectrum, disrupting biofilm across multiple gram-positive and gram-negative bacteria species. Upon biofilm disruption, bacteria regain antibiotic susceptibility. The drug is currently in phase I stage of clinical trial evaluation to treat Methicillin-resistant Staphylococcus aureus infections. TRL1068 has received more than $5M in grant funding from the NIH to facilitate preclinical development, including multiple animal proof-of-concept experiments.
- Delpazolid (LCB01-0371): LegoChem Biosciences
Delpazolid (LCB01 0371) is an oxazolidinone derivative antibacterial therapeutic, being developed by LegoChem Biosciences to treat Tuberculosis, Gram-positive infections; Methicillin-resistant Staphylococcus aureus infections; Vancomycin-resistant enterococcal infections.
Learn more about Methicillin-Resistant Staphylococcus Aureus Infection Drugs opportunities in our groundbreaking Methicillin-Resistant Staphylococcus Aureus Infection Research and development projects @ Methicillin-Resistant Staphylococcus Aureus Infection Unmet Needs
Methicillin-Resistant Staphylococcus Aureus Infections pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
- Oral
- Parenteral
- intravenous
- Subcutaneous
- Topical.
Methicillin-Resistant Staphylococcus Aureus Infection Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
Discover the latest advancements in Methicillin-Resistant Staphylococcus Aureus Infection Treatment by visiting our website. Stay informed about how we’re transforming the future @ Methicillin-Resistant Staphylococcus Aureus Infection Market Drivers and Barriers, and Future Perspectives
Scope of the Methicillin-Resistant Staphylococcus Aureus Infection Pipeline Report
- Coverage- Global
- Methicillin-Resistant Staphylococcus Aureus Infection Companies- Trellis Bioscience, LegoChem Biosciences, Aptorum Group, ContraFect, Crystalgenomics, Cellics Therapeutics, MicuRx, Oxford Antibiotic Group, Destiny Pharma, TSRL, Inc., TAXIS Pharmaceuticals, Basilea Pharmaceutica, Helperby Therapeutics, Akagera Medicines, Histogen, Alphamab Co. Ltd, Biocidium Pharmaceuticals, and others.
- Methicillin-Resistant Staphylococcus Aureus Infection Therapies- Retapamulin, Linezolid (Zyvox), Vancomycin, Nitric Oxide, Ceftaroline fosamil, Daptomycin, and others.
- Methicillin-Resistant Staphylococcus Aureus Infection Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Methicillin-Resistant Staphylococcus Aureus Infection Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Methicillin-Resistant Staphylococcus Aureus Infection Pipeline on our website @ Methicillin-Resistant Staphylococcus Aureus Infection Drugs and Companies
Table of Content
- Introduction
- Executive Summary
- Methicillin-Resistant Staphylococcus Aureus Infections: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Methicillin-Resistant Staphylococcus Aureus Infections – DelveInsight’s Analytical Perspective
- Mid Stage Products (Phase II)
- HY-004: Helperby therapeutics
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- TRL1068: Trellis Bioscience
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- EVX B1: Evaxion Biotech
- Drug profiles in the detailed report…..
- Inactive Products
- Methicillin-Resistant Staphylococcus Aureus Infections Key Companies
- Methicillin-Resistant Staphylococcus Aureus Infections Key Products
- Methicillin-Resistant Staphylococcus Aureus Infections- Unmet Needs
- Methicillin-Resistant Staphylococcus Aureus Infections- Market Drivers and Barriers
- Methicillin-Resistant Staphylococcus Aureus Infections- Future Perspectives and Conclusion
- Methicillin-Resistant Staphylococcus Aureus Infections Analyst Views
- Methicillin-Resistant Staphylococcus Aureus Infections Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/